Investor Library

StemRIMIR Library

All Timely Disclosure Information Financial Results Presentation Materials IR News

September 10, 2026	Timely Disclosure Information	StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
September 10, 2026	Timely Disclosure Information	StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
September 9, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2026 [Japanese GAAP]
September 9, 2026	Timely Disclosure Information	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
September 9, 2026	Timely Disclosure Information	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
August 3, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
July 22, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
July 13, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
July 8, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in ,South Korea
July 6, 2026	IR News	StemRIM Announces Publication of a Paper on Novel Finding about Contribution of Ectomesenchyme for Epidermal Stem Cell Formation
June 17, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
June 16, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
June 10, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Nine Months Ended April 30, 2026 [Japanese GAAP]
May 15, 2026	IR News	StemRIM Announces Publication of a Paper on a Physician-Initiated Phase 2 Clinical Trial of Redasemtide (HMGB1 Peptide) for Chronic Liver Disease
May 13, 2026	Timely Disclosure Information	StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock